Results 31 to 40 of about 12,493 (244)

Physicians' Experiences as Patients with Statin Side Effects: A Case Series. [PDF]

open access: yes, 2017
Physicians are among those prescribed statins and therefore, subject to potential statin adverse effects (AEs). There is little information on the impact of statin AEs on physicians affected by them. We sought to assess the character and impact of statin
Golomb, Beatrice Alexandra   +2 more
core   +2 more sources

Hallucinatory Side Effects of ADHD Drugs

open access: yesPediatric Neurology Briefs, 2009
Clinical trial and postmarketing surveillance data for drugs used in treatment of attention deficit hyperactivity disorder were analyzed to determine the frequency of hallucinations and other psychotic side effects, in a study at the US Food and Drug ...
J Gordon Millichap
doaj   +1 more source

Post-marketing safety surveillance of the rotavirus vaccine in India

open access: yesVaccine: X, 2023
Background: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India.
Gagandeep Kang   +9 more
doaj   +1 more source

Linked health data for pharmacovigilance in children : Perceived legal and ethical issues for stakeholders and data guardians [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Bond, Christine M   +4 more
core   +2 more sources

The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication. [PDF]

open access: yes, 2016
PurposeTo explore whether privacy restrictions developed to protect patients have complicated research within a 15-year surveillance study conducted with US cancer registries.MethodsData from enrolling 27 cancer registries over a 10-year period were ...
Andrews, Elizabeth B   +6 more
core   +1 more source

Trends and characteristics of accidental and intentional codeine overdose deaths in Australia [PDF]

open access: yes, 2015
Examines trends in codeine-related mortality rates in Australia, and the clinical and toxicological characteristics of codeine-related deaths. Abstract Objectives: To examine trends in codeine-related mortality rates in Australia, and the clinical and ...
Amanda Roxburgh   +6 more
core   +1 more source

Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines

open access: yesSaudi Pharmaceutical Journal, 2022
Introduction: Since December 2020, three COVID-19 vaccines have been authorized in the United States (U.S.) and were proceeded by large immunization programs. The aim of this study was to characterize the U.S.
Omar M. Albalawi   +4 more
doaj   +1 more source

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study [PDF]

open access: yesIntestinal Research, 2021
Background/Aims Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan.
Haruhiko Ogata   +4 more
doaj   +1 more source

Improving the external validity of clinical trials: the case of multiple chronic conditions [PDF]

open access: yes, 2013
The U.S. Department of Health and Human Services vision and strategic framework on multiple chronic conditions (MCCs) incorporates recommendations designed to facilitate research that will improve our knowledge about interventions and systems that will ...
Fortin, Martin, Smith, Susan M.
core   +4 more sources

Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data

open access: yesPharmacoepidemiology, 2023
Proton-pump inhibitors, PPIs, are widely prescribed and are available over the counter for prolonged reduction of stomach acid production and related disorders. PPIs irreversibly inhibit the hydrogen/potassium ATPase in gastric parietal cells.
Tigran Makunts   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy